3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Sarcoma
7
Gastrointestinal Stromal Tumors
4
Hemangiosarcoma
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Melanoma
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma Of Esophagus
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Liver Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Interventions
pembrolizumab
3
talimogene laherparepvec
1
spartalizumab
1
daromun
1
avelumab
1
Therapeutics
1
TTI-621
1
Radiation, Ionizing
1
Radiation
1
Proton Pump Inhibitors
1
Nivolumab
1
Mohs Surgery
1
Ipilimumab
1
Hydrocortisone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
spartalizumab
×
Sarcoma
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts